GERMANTOWN, Md., Oct. 14 /PRNewswire-FirstCall/ -- MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK), a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced that MiddleBrook President and CEO John Thievon will be presenting at the Rodman & Renshaw 10th Annual Healthcare Conference at the New York Palace Hotel in New York City on Nov. 11, 2008, at 12:00 p.m. (ET).

A live audio webcast of the presentation can be accessed by going to the Events section of MiddleBrook's Investor Relations web site at http://ir.middlebrookpharma.com. A replay of the webcast will be available later that day.

About Middlebrook Pharmaceuticals:

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on the development and commercialization of anti-infective drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The Company is developing anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in pulses are killed more efficiently than those under standard treatment regimens. Based on this finding, MiddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(R). The Company currently markets the Keflex(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) - the first and only once-daily amoxicillin product approved for marketing in the U.S. For more information on MiddleBrook, please visit www.middlebrookpharma.com.

SOURCE MiddleBrook Pharmaceuticals, Inc.